Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Bilateral Vallecular Cysts as a Cause of Dysphagia: Case Report and Literature Review
Romak, Jonathan J., Olsen, Steven M., Koch, Cody A., Ekbom, Dale C.

Mayo Clinic

International Journal of Otolaryngology | December 12, 2010 | Volume: 2010 | Issue: No issue available | Pages: 1-3

10.1155/2010/697583 | PMID 21197461 Get It

Cysts of the vallecula are rare, accounting for 10.5% to 20.1% of all laryngeal cysts. Vallecular cysts may present with diverse symptoms affecting the voice, airway, and swallowing. We describe the evaluation and treatment of a 70-year-old woman who presented with dysphagia caused by large bilateral vallecular cysts.
Phase III Trial of Prophylactic Cranial Irradiation Compared With Observation in Patients With Locally Advanced Non–Small-Cell Lung Cancer: Neurocognitive and Quality-of-Life Analysis
Sun, A. , Bae, Kyounghwa, Gore, Elizabeth , Movsas, Benjamin , Wong, Stuart J. , Meyers, Christina A., Bonner, James A. , Schild, Steven E. , Gaspar, Laurie E., Bogart, J.A., Werner‐Wasik, Maria, Choy, Hak, Schild, Steven

Mayo Clinic

Journal of Clinical Oncology | December 7, 2010 | Volume: 29 | Issue: 3 | Pages: 279-286

10.1200/jco.2010.29.6053 | PMID 21135267 Get It

Purpose There are scant data regarding the effects of prophylactic cranial irradiation (PCI) on neurocognitive function (NCF) and quality of life (QOL). Radiation Therapy Oncology Group trial 0214 showed no overall survival (OS) benefit for PCI in stage III non–small-cell lung cancer (NSCLC) at 1 year. However, there was a significant decrease in brain metastases (BM). This analysis focuses on the impact of PCI on NCF and QOL. Patients and Methods Patients with stage III NSCLC who completed definitive therapy without progression were randomly assigned to PCI or observation. NCF was assessed with Mini-Mental Status Examination (MMSE), Activities of Daily Living Scale (ADLS), and Hopkins Verbal Learning Test (HVLT). QOL was assessed with the European Organisation for Research and Treatment of Cancer (EORTC) core tool (QOL Questionnaire-QLQC30) and brain module (QLQBN20). Results There were no statistically significant differences at 1 year between the two arms in any component of the EORTC-QLQC30 or QLQBN20 (P > .05), although a trend for greater decline in patient-reported cognitive functioning with PCI was noted. There were no significant differences in MMSE (P = .60) or ADLS (P = .88). However, for HVLT, there was greater decline in immediate recall (P = .03) and delayed recall (P = .008) in the PCI arm at 1 year. Conclusion PCI in stage III NSCLC significantly decreases the risk of BM without improving 1-year OS. There were no significant differences in global cognitive function (MMSE) or QOL after PCI, but there was a significant decline in memory (HVLT) at 1 year. This study provides prospective data regarding the relative risks and benefits of PCI in this setting and the need to use sensitive cognitive assessments.
Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients With Locally Advanced Non–Small-Cell Lung Cancer: Primary Analysis of Radiation Therapy Oncology Group Study RTOG 0214
Gore, Elizabeth , Bae, Kyounghwa, Wong, Stuart J. , Sun, A. , Bonner, James A. , Schild, Steven E. , Gaspar, Laurie E., Bogart, J.A., Werner‐Wasik, Maria, Choy, Hak, Schild, Steven

Mayo Clinic

Journal of Clinical Oncology | December 7, 2010 | Volume: 29 | Issue: 3 | Pages: 272-278

10.1200/jco.2010.29.1609 | PMID 21135270 Get It

PurposeThis study was conducted to determine if prophylactic cranial irradiation (PCI) improves survival in locally advanced non–small-cell lung cancer (LA-NSCLC).Patients and MethodsPatients with stage III NSCLC without disease progression after treatment with surgery and/or radiation therapy (RT) with or without chemotherapy were eligible. Participants were stratified by stage (IIIA v IIIB), histology (nonsquamous v squamous), and therapy (surgery v none) and were randomly assigned to PCI or observation. PCI was delivered to 30 Gy in 15 fractions. The primary end point of the study was overall survival (OS). Secondary end points were disease-free survival (DFS), neurocognitive function (NCF), and quality of life. Kaplan-Meier and log-rank analyses were used for OS and DFS. The incidence of brain metastasis (BM) was evaluated with the logistic regression model.ResultsOverall, 356 patients were accrued of the targeted 1,058. The study was closed early because of slow accrual; 340 of the 356 patients were eligible. The 1-year OS (P = .86; 75.6% v 76.9% for PCI v observation) and 1-year DFS (P = .11; 56.4% v 51.2% for PCI v observation) were not significantly different. The hazard ratio for observation versus PCI was 1.03 (95% CI, 0.77 to 1.36). The 1-year rates of BM were significantly different (P = .004; 7.7% v 18.0% for PCI v observation). Patients in the observation arm were 2.52 times more likely to develop BM than those in the PCI arm (unadjusted odds ratio, 2.52; 95% CI, 1.32 to 4.80).ConclusionIn patients with stage III disease without progression of disease after therapy, PCI decreased the rate of BM but did not improve OS or DFS.
Spontaneous Epiglottic Hematoma Secondary to Supratherapeutic Anticoagulation
Koch, Cody A., Olsen, Steven M., Saleh, Amy M., Orvidas, Laura J.

Mayo Clinic

International Journal of Otolaryngology | November 7, 2010 | Volume: 2010 | Issue: No issue available | Pages: 1-3

10.1155/2010/201806 | PMID 21076680 Get It

Hemorrhage into the soft tissues of the airway represents a potentially life-threatening complication of long-term anticoagulation. We report the case of a chronically anticoagulated 37-year-old male who developed a spontaneous hematoma of the epiglottis secondary to a supra-therapeutic INR. Epiglottic hematoma should be considered in the differential of any anticoagulated patient presenting with upper airway compromise. The airway should be secured in a controlled fashion, and the coagulopathy should be rapidly corrected.
A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling
Hildebrand, Joanne M. , Luo, Zhenghua , Price-Troska, Tammy, Ziesmer, Steven C., Lin, Wai, Hostager, Bruce S. , Ansell, Stephen M. , Cerhan, James R. , Bishop, Gail A. , Novak, Anne J. , Manske, Michelle K. , Slager, Susan L. , Witzig, Thomas E. , Cerhan, James R

Mayo Clinic

Journal of Experimental Medicine | November 2, 2010 | Volume: 207 | Issue: 12 | Pages: 2569-2579

10.1084/jem.20100857 | PMID 21041452 Get It

The cytokine B cell activating factor (BAFF) and its receptor, BAFF receptor (BAFF-R), modulate signaling cascades critical for B cell development and survival. We identified a novel mutation in TNFRSF13C, the gene encoding human BAFF-R, that is present in both tumor and germline tissue from a subset of patients with non-Hodgkin lymphoma. This mutation encodes a His159Tyr substitution in the cytoplasmic tail of BAFF-R adjacent to the TRAF3 binding motif. Signaling through this mutant BAFF-R results in increased NF-κB1 and NF-κB2 activity and increased immunoglobulin production compared with the wild-type (WT) BAFF-R. This correlates with increased TRAF2, TRAF3, and TRAF6 recruitment to His159Tyr BAFF-R. In addition, we document a requirement for TRAF6 in WT BAFF-R signaling. Together, these data identify a novel lymphoma-associated mutation in human BAFF-R that results in NF-κB activation and reveals TRAF6 as a necessary component of normal BAFF-R signaling.
Unusual Case of Nonbacterial Thrombotic Endocarditis Attributable to Primary Antiphospholipid Syndrome
Vinales, Karyne L. , Gopalan, Radha , Lanza, Louis A., Lester, Steven J., Chaliki, Hari P.

Mayo Clinic

Circulation | September 20, 2010 | Volume: 122 | Issue: 12 | Pages: No page available

10.1161/circulationaha.110.954032 | PMID 20855665 Get It

Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features
Kumar, Shaji , Dispenzieri, Angela , Katzmann, Jerry A., Colby, Colin , Lacy, Martha Q. , Hayman, Suzanne R. , Leung, Nelson , Zeldenrust, Steve R., Ramı́rez-Alvarado, Marina , Clark, Raynell, Kyle, Robert A. , Rajkumar, S. Vincent , Larson, Dirk R. , Buadi, Francis K. , Zeldenrust, Steven R., Gertz, Morie A. , Rajkumar, S Vincent , Leung, Nelson , Dispenzieri, Angela , Ramirez-Alvarado, Marina

Mayo Clinic

Blood | August 26, 2010 | Volume: 116 | Issue: 24 | Pages: 5126-5129

10.1182/blood-2010-06-290668 | PMID 20798235 Get It

Abstract Immunoglobulin free light chains (FLCs) are the precursors of amyloid fibrils in primary amyloidosis (AL). We studied the relationship between FLC levels and clinical features in 730 patients with newly diagnosed AL. The plasma cell clone was λ in 72% patients, and κ in 28% patients. κ-AL had more GI tract and liver involvement, where as renal involvement was more with λ-AL. While the overall survival (OS) was similar for κ and λ-AL, the median OS for those without an identifiable serum heavy chain was significantly shorter (12.6 vs 29.9 months; P = .02). The OS was shorter among those with a higher dFLC (involved FLC−uninvolved FLC; κ > 29.4 mg/dL or λ > 18.2 mg/dL using median for cutoff); 10.9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL.
Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting
Thomas, Melanie B., Jaffe, Deborah, Choti, Michael M., Belghiti, Jacques, Curley, Steven A. , Fong, Yuman , Kerlan, Robert K., Merle, P., O’Neil, Bert H. , Poon, Ronnie T.P., Schwartz, Lawrence , Tepper, Joel E. , Yao, Francis Y. , Haller, Daniel G. , Mooney, Margaret , Schwartz, Lawrence H. , Fong, Yuman , Gores, Gregory J. , Venook, Alan P. , Schwartz, Lawrence H

Mayo Clinic

Journal of Clinical Oncology | August 3, 2010 | Volume: 28 | Issue: 25 | Pages: 3994-4005

10.1200/jco.2010.28.7805 | PMID 20679622 Get It

Hepatocelluar carcinoma (HCC) is the most common primary malignancy of the liver in adults and the third most common cause of cancer death worldwide. The incidence of HCC in the United States is rising steadily because of the prevalence of hepatitis C viral infection and other causes of hepatic cirrhosis. The majority of patients have underlying hepatic dysfunction, which complicates patient management and the search for safe and effective therapies. The Clinical Trials Planning Meeting (CTPM) in HCC was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee to identify the key knowledge gaps in HCC and define clinical research priorities. The CTPM structured its review according to current evidence-based treatment modalities in HCC and prioritized the recommendations on the basis of the patient populations representing the greatest unmet medical need.
Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis
Bhattacharyya, Sanjib , Curley, Steven A. , McNiven, Mark A. , Bhattacharya, Resham , Mukherjee, Priyabrata

Mayo Clinic

Proceedings of the National Academy of Sciences | August 2, 2010 | Volume: 107 | Issue: 33 | Pages: 14541-14546

10.1073/pnas.1006507107 | PMID 20679244 Get It

Treatment with monoclonal antibody (mAbs) is a viable therapeutic option in cancer. Recently, these mAbs such as cetuximab, herceptin, etc., have been used as targeting agents to selectively deliver chemotherapeutics to cancerous cells. However, mechanisms of nanoparticles-mAbs interactions with the target cells and its effect on intracellular trafficking and mechanism are currently unknown. In this paper, we demonstrate that the distinct patterning and dynamics of anti-EGFR (epidermal growth factor receptor) antibody cetuximab (C225)- induced EGFR internalization in pancreatic cancer cells with variable receptor expression is altered upon nanoconjugation. Nanoconjugation uniformly enhanced C225-induced EGFR endocytosis in PANC-1, AsPC-1, and MiaPaca-2 cells, influenced its compartmentalization and regulated the involvement of dynamin-2 in the endocytic processes. Receptor endocytosis and its intracellular trafficking were monitored by confocal microscopy and transmission electron microscopy. The role of dynamin-2 in EGFR endocytosis was determined after overexpressing either wild-type dynamin-2 or mutant dynamin-2 in pancreatic cancer cells followed by tracking the receptor-antibody complex internalization by confocal microscopy. Significantly, these findings demonstrate that the nanoconjugation cannot be construed as an innocuous reaction involved in attaching the targeting agent to the nanoparticle, instead it may distinctly alter the cellular processes at the molecular level, at least antibody induced receptor endocytosis. This information is critical for successful design of a nanoparticle-based targeted drug delivery system for future clinical translation.